计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175631-100μg |
100μg |
期货 ![]() |
| |
| Ab175631-1mg |
1mg |
期货 ![]() |
| |
| Ab175631-5mg |
5mg |
期货 ![]() |
| |
| Ab175631-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Pidilizumab (anti-PD-1), 程序性细胞死亡蛋白 1 抑制剂 |
|---|---|
| 别名 | 匹地利珠单抗 | 匹地利珠单抗(抗 PD-1) |
| 英文别名 | CD279 antibody | CD279 antigen antibody | hPD 1 antibody | hPD l antibody | hPD-1 antibody | hSLE1 antibody | PD 1 antibody | PD-1 antibody | PD1 antibody | PDCD 1 antibody | PDCD1_HUMAN antibody | PDCD1 antibody | Programmed cell death 1 antibody | Progr |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | PDCD1 |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 程序性细胞死亡蛋白 1 抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 147.14 kDa |
| 纯化方法 | Protein A purified |
| 物理外观 | Liquid |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1036730-42-3 |
| 分子类型 | 抗体 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
¥959.90
¥209.90
¥329.90
¥329.90
¥169.90
¥369.90
¥569.90
¥559.90
¥669.90
¥199.90
¥669.90
¥579.90
¥579.90
¥669.90
¥669.90
¥379.90
¥339.90
¥579.90
¥899.90
¥269.90
| 1. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A. (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.. Clin Cancer Res, 14 (10): (3044-51). [PMID:18483370] |
| 2. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012) T cell coinhibition and immunotherapy in human breast cancer.. Discov Med, 14 (77): (229-36). [PMID:23114578] |
| 3. Greaves P, Gribben JG. (2013) The role of B7 family molecules in hematologic malignancy.. Blood, 121 (5): (734-44). [PMID:23223433] |
| 4. Tang PA, Heng DY. (2013) Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.. Curr Oncol Rep, 15 (2): (98-104). [PMID:23263823] |
| 5. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR et al.. (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.. J Clin Oncol, 31 (33): (4199-206). [PMID:24127452] |
| 6. Bachy E, Coiffier B. (2014) Anti-PD1 antibody: a new approach to treatment of lymphomas.. Lancet Oncol, 15 (1): (7-8). [PMID:24332517] |
| 7. Hardy B, Galli M, Rivlin E, Goren L, Novogrodsky A. (1995) Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein.. Cancer Immunol Immunother, 40 (6): (376-82). [PMID:7627994] |
| 8. Hardy B, Yampolski I, Kovjazin R, Galli M, Novogrodsky A. (1994) A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.. Cancer Res, 54 (22): (5793-6). [PMID:7954401] |
| 9. Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A. (1997) A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.. Proc Natl Acad Sci USA, 94 (11): (5756-60). [PMID:9159146] |